Media about us

02 May 2017

Biopharma just can’t get enough of Epic Sciences

Juliet Preston / MedCityNews

Epic Sciences has to be one of the coolest kids on the biopharma block, with a new $40 million Series D financing round, a whopping 42 industry partnerships and over 200 clinical trials in the works, all built around its novel liquid biopsy platform. For a team of just 70, the San Diego, California startup is doing pretty well.

02 May 2017

With $40M in New Cash, Epic Sciences Advances Diagnostic for Late-Stage Prostate Cancer

Bruce V. Bigelow / Xconomy

When San Diego’s Epic Sciences raised $30 million almost three years ago, CEO Murali Prahalad told me he saw a big opportunity to use the company’s technology as a diagnostic test to assess how well a cancer patient is responding to specific anti-cancer drug regimens.

10 April 2017

Corneal inlays need your boost to hit their stride

John A. Hovanesian, MD, FACS / Healio

Recently, ReVision Optics announced the implantation of the 1,000th Raindrop corneal inlay in the United States since its approval last August. The AcuFocus Kamra corneal inlay, which was approved earlier, has now reached nearly 4,000 U.S. implants, according to a source at the company.

07 March 2017

New help for that bane of middle-age: blurry close-up vision

Lauran Neergaad, AP Medical Writer / Associated Press

Squinting while texting? Always losing your reading glasses? An eye implant that takes about 10 minutes to put in place is the newest in a list of surgical repairs for the blurry close-up vision that is a bane of middle age. But who's really a good candidate to toss their specs?

16 February 2017

Atlas to invest in extra capacity at STI test manufacturing partner Bespak

Dani Bancroft / InPharma Technologist.com

Atlas Genetics has said it will expand manufacturing capacity for cartridgebased STI tests at a UK facility owned by drug delivery technology firm Bespak Europe ltd.

15 February 2017

Liquid biopsies: The next frontier in cancer?

Ned Pagliarulo / BioPharmaDive

As immuno-oncology dazzles and pharma companies race to develop new cancer medicines, a similar boom is underway to speed up and improve the detection of cancers.

01 February 2017

Top 5 Vendors in the Pharmerging Market from 2017 to 2021: Technavio

Yahoo Finance

The pharmaceutical industry worldwide witnesses a dramatic regional shift to the pharmerging market, owing to the opportunities available. Considering the on-going trend of shift in global medicine dosage consumption to developing countries, about 55-60% of the global consumption should come from pharmerging markets by 2021. This will eventually lead to an incremental growth of around 25% from 2016 level.

24 January 2017

Struggling Marinus gets a bump out of a positive PhII snapshot

Arsalan Arif / Endpoints News

A lit­tle more than six months since its stock price was crushed by a failed late-stage pro­gram for its lead­ing — and only — drug, tiny biotech mi­cro­cap Mar­i­nus $MRNS saw its shares shoot up this morn­ing after it of­fered a pos­i­tive Phase II snap­shot on a hand­ful of pa­tients who suf­fer from a rare ge­netic ail­ment.

24 January 2017

Marinus gets a lifeline with new ganaxolone data

Ben Adams / Fierce Biotech

Micro cap Marinus Pharmaceuticals was up 28% premarket this morning on positive, early data from its midstage test of ganaxolone in a rare condition that causes severe seizures.

11 January 2017

JP Morgan Healthcare Conference, Day One: Genomic Health, Meridian Bioscience, Qiagen

Ed Winnick / GenomeWeb

The 35th Annual JP Morgan Healthcare Conference began here Monday with several life science research tools and diagnostic firms making presentations to investors and other attendees.